1. Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing
- Author
-
Pizza, Mariagrazia, Scarlato, Vincenzo, Masignani, Vega, Giuliani, Marzia Monica, Arico, Beatrice, Comanducci, Maurizio, Jennings, Gary T., Baldi, Lucia, Bartolini, Erika, Capecchi, Barbara, Galeotti, Cesira L., Luzzi, Enrico, Manetti, Roberto, Marchetti, Elisa, Mora, Marirosa, Nuti, Sandra, Ratti, Giulio, Santini, Laura, Savino, Silvana, Scarselli, Maria, Storni, Elisa, Zuo, Peijun, Broeker, Michael, Hundt, Erika, Knapp, Bernard, Orwell, George, Mason, Tanya, Tettelin, Herve, Hood, Derek W., Jeffries, Alex C., Saunders, Nigel J., Granoff, Dan M., Venter, J. Craig, Moxon, E. Richard, Grandi, Guido, and Rappuoli, Rino
- Subjects
Science and technology - Abstract
Neisseria meningitidis is a major cause of bacterial septicemia and meningitis. Sequence variation of surface-exposed proteins and cross-reactivity of the serogroup B capsular polysaccharide with human tissues have hampered efforts to develop a successful vaccine. To overcome these obstacles, the entire genome sequence of a virulent serogroup B strain (MC58) was used to identify vaccine candidates. A total of 350 candidate antigens were expressed in Escherichia coli, purified, and used to immunize mice. The sera allowed the identification of proteins that are surface exposed, that are conserved in sequence across a range of strains, and that induce a bactericidal antibody response, a property known to corm[ate with vaccine efficacy in humans., Meningococcal meningitis and sepsis are devastating diseases that can kill children and young adults within hours despite the availability of effective antibiotics. The diseases are caused by Neisseria meningitidis, a [...]
- Published
- 2000